Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.

ABSTRACT: The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence of immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies and some patients even experience severe adverse events. Prognostic and predictive biomarkers are therefore needed in order to select patients who will respond. Nowadays, the only validated biomarker is the PD-L1 expression, but its predictive value remains imperfect, and it does not offer any certainty of a sustained response to treatment. With recent progresses in molecular biology, genome sequencing techniques, and the understanding of the immune microenvironment of the tumor and its host, new molecular features have been highlighted. There are evidence in favor of the positive

SUBMITTER: Pabst L 

PROVIDER: S-EPMC10145126 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature